FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug

JAMA. 2017 Nov 21;318(19):1861-1862. doi: 10.1001/jama.2017.15218.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use
  • Drug Approval*
  • Drug Costs*
  • Humans
  • Neoplasms / drug therapy*
  • Recombinant Fusion Proteins / economics*
  • Recombinant Fusion Proteins / therapeutic use
  • T-Lymphocytes / transplantation*
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • Recombinant Fusion Proteins